Welcome to Idorsia

Idorsia announced
Full Year 2018
Results

We've made
outstanding
progress
in 2018 -
interested to
learn more?

Our key assets have
the potential to
transform treatment in
the target indications...

Read about how our IT department
achieved operational independence
ahead of schedule...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s future success entirely depends on our people.

Idorsia's development compounds target a number of different diseases.

07 Feb 2019	Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3
05 Feb 2019	Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
07 Jan 2019	Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus

Event	When
First Quarter 2019 Financial Results reporting*	April 18, 2019
Annual General Meeting of Shareholders 2019	May 3, 2019
Half-Year 2019 Financial Results reporting*	July 23, 2019
Nine-months 2019 Financial Results reporting*	October 22, 2019

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 10:29:57 CET

16.81 CHF

+0.07 (+0.42 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland